APA (7th ed.) Citation

K, M., K, G., K, K., T, S., M, C., N, S., . . . W, C. (2023). Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines, 11(12), . https://doi.org/10.3390/vaccines11121826

Chicago Style (17th ed.) Citation

K, Mahasongkram, Glab-Ampai K, Kaewchim K, Saenlom T, Chulanetra M, Sookrung N, Nathalang O, and Chaicumpa W. "Agonistic Bivalent Human ScFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities Against Cancer." Vaccines 11, no. 12 (2023). https://doi.org/10.3390/vaccines11121826.

MLA (9th ed.) Citation

K, Mahasongkram, et al. "Agonistic Bivalent Human ScFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities Against Cancer." Vaccines, vol. 11, no. 12, 2023, https://doi.org/10.3390/vaccines11121826.